Two Sigma Advisers LP Has $1.89 Million Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA)

Two Sigma Advisers LP increased its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 195.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 831,900 shares of the company's stock after acquiring an additional 550,700 shares during the quarter. Two Sigma Advisers LP owned about 1.70% of Cabaletta Bio worth $1,888,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Two Sigma Investments LP increased its position in Cabaletta Bio by 78.8% during the fourth quarter. Two Sigma Investments LP now owns 751,894 shares of the company's stock worth $1,707,000 after acquiring an additional 331,417 shares during the period. Raiffeisen Bank International AG bought a new position in Cabaletta Bio during the fourth quarter worth $493,000. Point72 Asset Management L.P. increased its position in Cabaletta Bio by 89.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,265,882 shares of the company's stock worth $2,874,000 after acquiring an additional 598,607 shares during the period. Integral Health Asset Management LLC increased its holdings in Cabaletta Bio by 11.1% in the 4th quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company's stock valued at $1,135,000 after buying an additional 50,000 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in Cabaletta Bio in the 4th quarter valued at $199,000.

Cabaletta Bio Stock Performance

NASDAQ CABA traded up $0.12 during trading hours on Tuesday, reaching $2.18. 2,077,774 shares of the company's stock were exchanged, compared to its average volume of 1,561,114. Cabaletta Bio, Inc. has a one year low of $0.99 and a one year high of $13.50. The company's 50-day moving average is $1.40 and its two-hundred day moving average is $2.03. The company has a market capitalization of $110.62 million, a price-to-earnings ratio of -1.01 and a beta of 2.81.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04). Research analysts predict that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Morgan Stanley cut their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 1st. UBS Group cut their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday, April 1st. Finally, Guggenheim upped their price target on Cabaletta Bio from $23.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $20.33.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.